Hologic, Inc. logo
Hologic, Inc. (HOLX)
Compare

Hologic, Inc. (HOLX) PE Ratio: 31.67

Is Hologic, Inc.’s P/E ratio high or low?

Hologic, Inc.'s P/E ratio of 31.67 is 39% above its 5-year average of 22.83, near the high end of its 5-year range (8.30–40.97).

As of Thursday, June 11, 2026. 12.61% above its 12-month average of 28.12.

PE Ratio (31.67) = Close Price ($76.01) / Diluted TTM EPS ($2.40)

HOLX PE Ratio Chart

HOLX PE Ratio
31.67+63.84% 1Y
Zoom

HOLX Average PE Ratio Chart

HOLX Current vs Average PE Ratio Chart

HOLX PE Ratio Metrics

PE RATIO

31.67

PE RATIO AVG TTM

28.12

PE RATIO AVG 3Y

30.08

PE RATIO AVG 5Y

22.83

PE RATIO AVG 10Y

24.84

PE RATIO AVG 15Y

47.20

PE RATIO AVG 20Y

52.61

CURRENT VS TTM AVG

+12.61%

CURRENT VS 3Y AVG

+5.29%

CURRENT VS 5Y AVG

+38.75%

CURRENT VS 10Y AVG

+27.51%

CURRENT VS 15Y AVG

-32.90%

CURRENT VS 20Y AVG

-39.80%

HOLX Competitors' PE Ratio

NAMEMARKET CAPPE RATIOTTM3Y5Y
Hologic, Inc. (HOLX)$16.97B31.6728.1230.0822.83
Moderna, Inc. (MRNA)$18.71BN/A15.4632.5132.51
Solventum Corporation (SOLV)$13.72B9.7018.8717.0717.07
Align Technology, Inc. (ALGN)$12.27B28.7129.2742.8547.76
BioNTech SE (BNTX)$22.39BN/A55.7322.6282.47
Mettler-Toledo International Inc. (MTD)$22.82B26.4331.9832.7936.43
United Therapeutics Corporation (UTHR)$23.15B20.1617.0314.9316.04
Waters Corporation (WAT)$23.21B46.1531.9130.9230.43
Baxter International Inc. (BAX)$10.58BN/A44.5334.4137.43
Charles River Laboratories International, Inc. (CRL)$8.94BN/A225.6691.3972.20

P/E vs. its own history

At 31.7, P/E is in its normal range, sitting higher than 46% of its 20-year history.

20-year low

8.3

median

34.7

20-year high

499.5

cheaperricher

P/E Comparison

Trailing P/E

31.7

Forward P/E

17.2

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$76.01

÷

Forward EPS (Est.)

$4.42

=

Forward P/E

17.21

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

Hologic, Inc. PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Hologic, Inc. PE Ratio FAQ

What is the P/E ratio for Hologic, Inc. (HOLX)?
The P/E ratio for HOLX stock is 31.67.
Is Hologic, Inc.'s P/E ratio high or low?
Hologic, Inc.'s P/E ratio of 31.67 is 39% above its 5-year average of 22.83, near the high end of its 5-year range (8.30–40.97).
What is the TTM average P/E ratio for Hologic, Inc. (HOLX)?
The TTM average P/E ratio for HOLX stock is 28.12.
What is the 3Y average P/E ratio for Hologic, Inc. (HOLX)?
The 3Y average P/E ratio for HOLX stock is 30.08.
What is the 5Y average P/E ratio for Hologic, Inc. (HOLX)?
The 5Y average P/E ratio for HOLX stock is 22.83.
What is the 10Y average P/E ratio for Hologic, Inc. (HOLX)?
The 10Y average P/E ratio for HOLX stock is 24.84.
What is the 15Y average P/E ratio for Hologic, Inc. (HOLX)?
The 15Y average P/E ratio for HOLX stock is 47.20.
What is the 20Y average P/E ratio for Hologic, Inc. (HOLX)?
The 20Y average P/E ratio for HOLX stock is 52.61.

Hologic, Inc. PE Ratio History

DATEPE RATIO
2026-04-0731.67
2026-04-0631.67
2026-04-0231.52
2026-04-0131.50
2026-03-3131.50
2026-03-3031.48
2026-03-2731.53
2026-03-2631.54
2026-03-2531.47
2026-03-2431.48
2026-03-2331.52
2026-03-2031.42
2026-03-1931.39
2026-03-1831.31
2026-03-1731.27
2026-03-1631.31
2026-03-1331.30
2026-03-1231.34
2026-03-1131.42
2026-03-1031.48
2026-03-0931.50
2026-03-0631.56
2026-03-0531.56
2026-03-0431.53
2026-03-0331.44
2026-03-0231.44
2026-02-2731.40
2026-02-2631.35
2026-02-2531.39
2026-02-2431.40
2026-02-2331.43
2026-02-2031.43
2026-02-1931.31
2026-02-1831.33
2026-02-1731.31
2026-02-1331.27
2026-02-1231.21
2026-02-1131.29
2026-02-1031.31
2026-02-0931.26
2026-02-0631.17
2026-02-0531.13
2026-02-0431.08
2026-02-0331.10
2026-02-0231.14
2026-01-3031.22
2026-01-2931.24
2026-01-2830.28
2026-01-2730.32
2026-01-2630.32
2026-01-2330.26
2026-01-2230.29
2026-01-2130.30
2026-01-2030.29
2026-01-1630.23
2026-01-1530.25
2026-01-1430.31
2026-01-1330.19
2026-01-1230.19
2026-01-0930.19
2026-01-0830.19
2026-01-0730.23
2026-01-0630.21
2026-01-0530.14
2026-01-0230.06
2025-12-3130.04
2025-12-3030.06
2025-12-2930.04
2025-12-2630.04
2025-12-2430.04
2025-12-2330.19
2025-12-2230.21
2025-12-1930.22
2025-12-1830.22
2025-12-1730.21
2025-12-1630.25
2025-12-1530.32
2025-12-1230.24
2025-12-1130.17
2025-12-1030.17
2025-12-0930.20
2025-12-0830.18
2025-12-0530.23
2025-12-0430.19
2025-12-0330.25
2025-12-0230.17
2025-12-0130.18
2025-11-2830.23
2025-11-2630.16
2025-11-2530.19
2025-11-2430.15
2025-11-2129.98
2025-11-2029.89
2025-11-1929.91
2025-11-1829.88
2025-11-1730.76
2025-11-1430.77
2025-11-1330.81
2025-11-1230.94
2025-11-1130.95
2025-11-1030.83
2025-11-0730.75
2025-11-0630.77
2025-11-0530.80
2025-11-0430.75
2025-11-0330.73
2025-10-3130.67
2025-10-3030.68
2025-10-2930.70
2025-10-2830.71
2025-10-2730.68
2025-10-2430.70
2025-10-2330.66
2025-10-2230.68
2025-10-2130.70
2025-10-2029.82
2025-10-1728.98
2025-10-1628.42
2025-10-1527.80
2025-10-1427.35
2025-10-1327.18
2025-10-1028.12
2025-10-0928.47
2025-10-0828.36
2025-10-0728.10
2025-10-0627.94
2025-10-0328.31
2025-10-0228.18
2025-10-0127.82
2025-09-3028.00
2025-09-2927.86
2025-09-2627.89
2025-09-2527.30
2025-09-2427.55
2025-09-2328.07
2025-09-2227.92
2025-09-1927.52
2025-09-1828.33
2025-09-1728.30
2025-09-1626.28
2025-09-1526.47
2025-09-1226.74
2025-09-1127.54
2025-09-1027.18
2025-09-0927.68
2025-09-0827.61
2025-09-0527.70
2025-09-0427.55
2025-09-0327.49
2025-09-0227.64
2025-08-2927.85
2025-08-2827.64
2025-08-2727.69
2025-08-2627.65
2025-08-2527.85
2025-08-2228.32
2025-08-2127.87
2025-08-2028.53
2025-08-1928.14
2025-08-1827.91
2025-08-1528.14
2025-08-1428.24
2025-08-1328.62
2025-08-1228.20
2025-08-1128.21
2025-08-0828.24
2025-08-0728.19
2025-08-0627.76
2025-08-0528.14
2025-08-0428.18
2025-08-0127.87
2025-07-3127.73
2025-07-3027.42
2025-07-2927.86
2025-07-2827.72
2025-07-2528.06
2025-07-2427.89
2025-07-2327.83
2025-07-2227.58
2025-07-2126.87
2025-07-1827.00
2025-07-1727.01
2025-07-1626.95
2025-07-1526.69
2025-07-1427.27
2025-07-1127.73
2025-07-1028.21
2025-07-0927.78
2025-07-0827.38
2025-07-0727.16
2025-07-0327.33
2025-07-0227.55
2025-07-0127.57
2025-06-3027.49
2025-06-2727.43
2025-06-2627.47
2025-06-2527.12
2025-06-2427.35
2025-06-2327.19
2025-06-2027.21
2025-06-1826.99
2025-06-1727.06
2025-06-1627.50
2025-06-1327.32
2025-06-1227.52
2025-06-1127.25
2025-06-1027.49
2025-06-0927.24
2025-06-0627.14
2025-06-0526.61
2025-06-0426.40
2025-06-0326.60
2025-06-0226.16
2025-05-3026.23
2025-05-2926.55
2025-05-2826.88
2025-05-2726.23
2025-05-2322.90
2025-05-2222.99
2025-05-2123.13
2025-05-2023.83
2025-05-1923.81
2025-05-1623.96
2025-05-1523.52
2025-05-1423.36
2025-05-1324.10
2025-05-1224.81
2025-05-0923.95
2025-05-0823.70
2025-05-0723.39
2025-05-0622.41
2025-05-0522.25
2025-05-0222.85
2025-05-0118.07
2025-04-3018.36
2025-04-2918.41
2025-04-2818.32
2025-04-2518.30
2025-04-2418.39
2025-04-2318.34
2025-04-2218.36
2025-04-2117.96
2025-04-1718.16
2025-04-1617.82
2025-04-1518.25
2025-04-1418.56
2025-04-1118.25
2025-04-1018.03
2025-04-0918.71
2025-04-0818.44
2025-04-0719.33
2025-04-0419.20
2025-04-0319.46
2025-04-0219.10
2025-04-0119.36
2025-03-3119.49
2025-03-2819.34
2025-03-2719.66
2025-03-2619.39
2025-03-2519.18

Showing the most recent 260 of 3,339 data points. The chart above shows the full history.

About Hologic, Inc.

Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.

Marlborough, MA
7,063 employees
Healthcare / Medical - Instruments & Supplies
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Paul Malenchini